Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Tiragolumab Consolidation in LS-SCLC
NCT04308785Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Atezolizumab + Tiragolumab with Atezolizumab + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 48 months. Started Dec 2021; status: terminated.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04308785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308785.